$ATIP
ATI Physical Therapy, Inc.

2020 Q2 Form 10-Q Financial Statement

#000181584920000004 Filed on September 16, 2020

View on sec.gov

Income Statement

Concept 2020 Q2
Revenue $107.8M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $24.79M
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $9.718M
YoY Change
% of Gross Profit
Operating Expenses $24.79M
YoY Change
Operating Profit -$13.65M
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $44.10M
YoY Change
Pretax Income -$15.62K
YoY Change
Income Tax $3.600M
% Of Pretax Income
Net Earnings $2.741M
YoY Change
Net Earnings / Revenue 2.54%
Basic Earnings Per Share $0.02
Diluted Earnings Per Share $0.02
COMMON SHARES
Basic Shares Outstanding 128.3M shares
Diluted Shares Outstanding 128.3M shares

Balance Sheet

Concept 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.00K
YoY Change
Cash & Equivalents $142.0M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $25.00K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $84.27K
YoY Change
Total Long-Term Assets $84.27K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $25.00K
Total Long-Term Assets $84.27K
Total Assets $109.3K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $99.89K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $99.89K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $99.89K
Total Long-Term Liabilities $0.00
Total Liabilities $99.89K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$15.62K
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $0.00
YoY Change
Total Liabilities & Shareholders Equity $109.3K
YoY Change

Cashflow Statement

Concept 2020 Q2
OPERATING ACTIVITIES
Net Income $2.741M
YoY Change
Depreciation, Depletion And Amortization $9.718M
YoY Change
Cash From Operating Activities $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $25.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $25.00K
YoY Change
NET CHANGE
Cash From Operating Activities $0.00
Cash From Investing Activities
Cash From Financing Activities $25.00K
Net Change In Cash $25.00K
YoY Change
FREE CASH FLOW
Cash From Operating Activities $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 dei Amendment Flag
AmendmentFlag
false
CY2020Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2020Q2 dei Entity Central Index Key
EntityCentralIndexKey
0001815849
CY2020Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q2 dei Document Type
DocumentType
10-Q
CY2020Q2 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q2 dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
CY2020Q2 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q2 dei Entity File Number
EntityFileNumber
001-39439
CY2020Q2 dei Entity Registrant Name
EntityRegistrantName
FORTRESS VALUE ACQUISITION CORP. II
CY2020Q2 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q2 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1408039
CY2020Q2 dei Entity Address Address Line1
EntityAddressAddressLine1
1345 Avenue of the Americas
CY2020Q2 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2020Q2 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2020Q2 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10105
CY2020Q2 dei City Area Code
CityAreaCode
212
CY2020Q2 dei Local Phone Number
LocalPhoneNumber
798-6100
CY2020Q2 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2020Q2 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q2 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q2 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q2 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q2 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020Q2 dei Entity Shell Company
EntityShellCompany
true
CY2020Q2 us-gaap Cash
Cash
25000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
25000 USD
CY2020Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
84265 USD
CY2020Q2 us-gaap Assets
Assets
109265 USD
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
99885 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
99885 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 faii Redemption Price Per Warrant
RedemptionPricePerWarrant
0.01
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24137 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15620 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
9380 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109265 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15620 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-15620 USD
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8625000 shares
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
0 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-15620 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
9380 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-15620 USD
CY2020Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
15620 USD
CY2020Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0 USD
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25000 USD
CY2020Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
25000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25000 USD
CY2020Q2 faii Offering Costs Accounts Payable And Accrued Expenses Noncash
OfferingCostsAccountsPayableAndAccruedExpensesNoncash
84265 USD
CY2020Q2 us-gaap Use Of Estimates
UseOfEstimates
The preparation of the condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period.        Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed as of June 30, 2020, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
CY2020Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 USD
CY2020Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2020Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2020Q2 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which at times may exceed the Federal depository insurance coverage of $250,000. As of June 30, 2020, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000 USD
CY2020Q2 faii Common Stock Threshold Trading Days
CommonStockThresholdTradingDays
20 day
CY2020Q2 faii Common Stock Threshold Consecutive Trading Days
CommonStockThresholdConsecutiveTradingDays
30 day
CY2020Q2 faii Class Of Warrant Or Right Blackout Trading Period After Completion Of Business Combination
ClassOfWarrantOrRightBlackoutTradingPeriodAfterCompletionOfBusinessCombination
P30D
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 faii Warrants Exercise Period Following Business Combination
WarrantsExercisePeriodFollowingBusinessCombination
P30D
CY2020Q2 faii Warrants Exercise Period Following Initial Public Offering
WarrantsExercisePeriodFollowingInitialPublicOffering
P12M
CY2020Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2020Q2 faii Restriction Period For Transfer Assignment Or Sale
RestrictionPeriodForTransferAssignmentOrSale
P30D
CY2020Q2 faii Numberof Daysfor Written Noticeof Redemption
NumberofDaysforWrittenNoticeofRedemption
P30D
CY2020Q2 faii Minimum Threshold Priceof Common Stock Specifiedto Send Noticeof Redemptiontothe Warrant Holders
MinimumThresholdPriceofCommonStockSpecifiedtoSendNoticeofRedemptiontotheWarrantHolders
18.00
CY2020Q2 faii Price Threshold Of Newly Issued Stock To Cause Adjustment Of Exercise Warrant Price
PriceThresholdOfNewlyIssuedStockToCauseAdjustmentOfExerciseWarrantPrice
9.20
CY2020Q2 faii Percentageof Warrant Exercise Price Adjustedto Price Receivedin New Issuance
PercentageofWarrantExercisePriceAdjustedtoPriceReceivedinNewIssuance
1.15

Files In Submission

Name View Source Status
0001815849-20-000004-index-headers.html Edgar Link pending
0001815849-20-000004-index.html Edgar Link pending
0001815849-20-000004.txt Edgar Link pending
0001815849-20-000004-xbrl.zip Edgar Link pending
exhibit311-10xqxfortre.htm Edgar Link pending
exhibit312-10xqxfortre.htm Edgar Link pending
exhibit321-10xqxfortre.htm Edgar Link pending
exhibit322-10xqxfortre.htm Edgar Link pending
faii-20200630.htm Edgar Link pending
faii-20200630.xsd Edgar Link pending
faii-20200630_cal.xml Edgar Link unprocessable
faii-20200630_def.xml Edgar Link unprocessable
faii-20200630_htm.xml Edgar Link completed
faii-20200630_lab.xml Edgar Link unprocessable
faii-20200630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending